Mapping of colorectal carcinoma diseases with activation of Wnt/beta-catenin signalling pathway using hierarchical clustering approach

2021 ◽  
pp. jclinpath-2020-207144
Author(s):  
Jean-François Mosnier ◽  
Fabrice Airaud ◽  
Sylvie Métairie ◽  
Christelle Volteau ◽  
Stéphane Bezieau ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Hierarchical Clustering ◽  
Wnt Signalling ◽  
Signalling Pathway ◽  
Low Grade ◽  
Beta Catenin ◽  
Intestinal Differentiation ◽  
Wnt Signalling Pathway ◽  
Pathway Activation ◽  
High Level

AimsTo map the colorectal carcinoma (CRC) diseases with significant Wnt signalling pathway activation for delineating their clinicopathological and molecular profiles.MethodsMapping is based on hierarchical clustering analyses of a series of 283 CRCs. Data tabulated were histopathological patterns, immunophenotypic differentiation, RAS, RAF, CTNNB1 mutations and microsatellite instability status, tumour-infiltrating lymphocytes (TILs) and genetic setting. Beta-catenin expression in more than 10% of cell nuclei in the centre of tumour serves as a surrogate marker of significant activation of Wnt signalling pathway.ResultsNuclei beta-catenin expression was present in 95% of CRCs; 56% of them met the criteria of high level of nuclei beta-catenin expression (≥10%). Proportion of beta-catenin positive nuclei was significantly higher in younger patients, rectal and left-sided colonic carcinomas. CRCs with high level of nuclei beta-catenin expression were regrouped into three clusters: (1) microsatellite stability (MSS) CRCs with no constitutive MAPK pathway activation including 90% of low-grade adenocarcinoma, NOS, with intestinal differentiation without TILs; (2) RAS-mutated MSS CRCs including low-grade adenocarcinoma, NOS, with intestinal differentiation and mucinous adenocarcinoma without TILs; (3) MSI-H CRCs including both BRAF-mutated CRCs evolving from serrated pathway and CTNNB1-mutated CRCs associated with Lynch syndrome.ConclusionsMSS low-grade adenocarcinoma, NOS, with intestinal differentiation without TILs (‘crypt-like adenocarcinoma’) might be the morphological pending of canonical molecular subtype of CRC defined as displayed molecular epithelial differentiation and upregulation of WNT in consensus molecular classification of CRC.

003.Expression of secreted frizzled related protein-4 (sFRP-4) and associated Wnt signalling in cancer and apoptosis

2005 ◽  
Vol 17 (9) ◽  
pp. 63 ◽  
Author(s):  
A. Dharmarajan ◽  
N. Zeps ◽  
S. McLaren
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Wnt Signalling ◽  
Conditioned Media ◽  
Signalling Pathway ◽  
Beta Catenin ◽  
Related Protein ◽  
Human Breast ◽  
Wnt Signalling Pathway ◽  
Mcf 7

We examined the interplay between Wnt and secreted frizzled related protein-4 (sFRP4) in estradiol induced cell growth in breast cancer cells (MCF-7), and also determined the in vivo distribution of sFRP-4 in human breast cancer. MCF-7 cells were treated with estradiol, sFRP-4 conditioned media and a combination of the two. Real-time RT-PCR and Western blot analysis were used to determine the expression of the sFRP-4 and its associated Wnt signalling molecules following treatment. Immunohistochemistry was performed to examine sFRP-4 expression patterns in human breast cancers. Estradiol treatment up-regulated the expression of the Wnt signalling genes Wnt-10b, beta-catenin and fz-4 (P < 0.001 for all genes). This up-regulation was not associated with an increase in the Wnt signalling pathway as measured by the levels of active beta-catenin. sFRP-4 conditioned media reduced MCF-7 cell proliferation, down-regulated the Wnt signalling genes beta-catenin and fz-4 as well as down-regulating wnt signalling activity. sFRP-4 was able to reduce the proliferation of estradiol stimulated MCF-7 cells. Cytoplasmic sFRP-4 protein was expressed in all breast tumours examined, with intense staining evident in the lobular carcinoma in situ and the ductal carcinoma. These data demonstrate that sFRP-4 is a potent inhibitor of the Wnt signalling pathway in MCF-7 cells, acting not only to down-regulate the activity of the wnt signalling pathway, but also down-regulate the transcription of Wnt signalling genes. The results of these in vitro and immunohistochemical experiments warrant further investigation as to whether sFRP-4 expression can be indicative of prognosis in human breast cancer. In addition to breast cancer, we have also examined the role of sFRP-4 in other cancers such as ovarian and prostate.

Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis

Pathology ◽  
2007 ◽  
Vol 39 (3) ◽  
pp. 319-325 ◽  
Author(s):  
Yang Jilong ◽  
Wang Jian ◽  
Zhou Xiaoyan ◽  
Li Xiaoqiu ◽  
Zhu Xiongzeng
Keyword(s):  
Wnt Signalling ◽  
Signalling Pathway ◽  
Beta Catenin ◽  
Wnt Signalling Pathway

GSK3 takes centre stage more than 20 years after its discovery

2001 ◽  
Vol 359 (1) ◽  
pp. 1-16 ◽  
Author(s):  
Sheelagh FRAME ◽  
Philip COHEN
Keyword(s):  
Substrate Specificity ◽  
Therapeutic Potential ◽  
Glycogen Synthase ◽  
Glycogen Metabolism ◽  
Wnt Signalling ◽  
Signalling Pathway ◽  
Dimensional Structure ◽  
Entire Body ◽  
Wnt Signalling Pathway ◽  
Wnt Proteins

Identified originally as a regulator of glycogen metabolism, glycogen synthase kinase-3 (GSK3) is now a well-established component of the Wnt signalling pathway, which is essential for setting up the entire body pattern during embryonic development. It may also play important roles in protein synthesis, cell proliferation, cell differentiation, microtubule dynamics and cell motility by phosphorylating initiation factors, components of the cell-division cycle, transcription factors and proteins involved in microtubule function and cell adhesion. Generation of the mouse knockout of GSK3β, as well as studies in neurons, also suggest an important role in apoptosis. The substrate specificity of GSK3 is unusual in that efficient phosphorylation of many of its substrates requires the presence of another phosphorylated residue optimally located four amino acids C-terminal to the site of GSK3 phosphorylation. Recent experiments, including the elucidation of its three-dimensional structure, have enhanced our understanding of the molecular basis for the unique substrate specificity of GSK3. Insulin and growth factors inhibit GSK3 by triggering its phosphorylation, turning the N-terminus into a pseudosubstrate inhibitor that competes for binding with the ‘priming phosphate’ of substrates. In contrast, Wnt proteins inhibit GSK3 in a completely different way, by disrupting a multiprotein complex comprising GSK3 and its substrates in the Wnt signalling pathway, which do not appear to require a ‘priming phosphate’. These latest findings have generated an enormous amount of interest in the development of drugs that inhibit GSK3 and which may have therapeutic potential for the treatment of diabetes, stroke and Alzheimer's disease.

scholarly journals Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β

2003 ◽  
Vol 89 (7) ◽  
pp. 1298-1304 ◽  
Author(s):  
K Rask ◽  
A Nilsson ◽  
M Brännström ◽  
P Carlsson ◽  
P Hellberg ◽  
...  
Keyword(s):  
Wnt Signalling ◽  
Signalling Pathway ◽  
Wnt Signalling Pathway ◽  
Epithelial Tumours

scholarly journals Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer

2013 ◽  
Vol 230 (2) ◽  
pp. 194-204 ◽  
Author(s):  
Yan Jia ◽  
Yunsheng Yang ◽  
Malcolm V Brock ◽  
Qimin Zhan ◽  
James G Herman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epigenetic Regulation ◽  
Human Lung ◽  
Wnt Signalling ◽  
Signalling Pathway ◽  
Human Lung Cancer ◽  
Wnt Signalling Pathway

scholarly journals Is resistant starch protective against colorectal cancer via modulation of the WNT signalling pathway?

2015 ◽  
Vol 74 (3) ◽  
pp. 282-291 ◽  
Author(s):  
Fiona C. Malcomson ◽  
Naomi D. Willis ◽  
John C. Mathers
Keyword(s):  
Colorectal Cancer ◽  
Cell Proliferation ◽  
Resistant Starch ◽  
Wnt Pathway ◽  
Wnt Signalling ◽  
Signalling Pathway ◽  
Wnt Signalling Pathway ◽  
Crypt Cell Proliferation ◽  
And Migration ◽  
Epigenetic Modulation

Epidemiological and experimental evidence suggests that non-digestible carbohydrates (NDC) including resistant starch are protective against colorectal cancer. These anti-neoplastic effects are presumed to result from the production of the SCFA, butyrate, by colonic fermentation, which binds to the G-protein-coupled receptor GPR43 to regulate inflammation and other cancer-related processes. The WNT pathway is central to the maintenance of homeostasis within the large bowel through regulation of processes such as cell proliferation and migration and is frequently aberrantly hyperactivated in colorectal cancers. Abnormal WNT signalling can lead to irregular crypt cell proliferation that favours a hyperproliferative state. Butyrate has been shown to modulate the WNT pathway positively, affecting functional outcomes such as apoptosis and proliferation. Butyrate's ability to regulate gene expression results from epigenetic mechanisms, including its role as a histone deacetylase inhibitor and through modulating DNA methylation and the expression of microRNA. We conclude that genetic and epigenetic modulation of the WNT signalling pathway may be an important mechanism through which butyrate from fermentation of resistant starch and other NDC exert their chemoprotective effects.

scholarly journals WNK regulates Wnt signalling and β-Catenin levels by interfering with the interaction between β-Catenin and GID

2020 ◽  
Vol 3 (1) ◽  
Author(s):  
Atsushi Sato ◽  
Masahiro Shimizu ◽  
Toshiyasu Goto ◽  
Hiroyuki Masuno ◽  
Hiroyuki Kagechika ◽  
...  
Keyword(s):  
Ubiquitin Ligase ◽  
Therapeutic Target ◽  
E3 Ubiquitin Ligase ◽  
Wnt Signalling ◽  
Signalling Pathway ◽  
Tumour Development ◽  
Wnt Signalling Pathway

Abstractβ-Catenin is an important component of the Wnt signalling pathway. As dysregulation or mutation of this pathway causes many diseases, including cancer, the β-Catenin level is carefully regulated by the destruction complex in the Wnt signalling pathway. However, the mechanisms underlying the regulation of β-Catenin ubiquitination and degradation remain unclear. Here, we find that WNK (With No Lysine [K]) kinase is a potential regulator of the Wnt signalling pathway. We show that WNK protects the interaction between β-Catenin and the Glucose-Induced degradation Deficient (GID) complex, which includes an E3 ubiquitin ligase targeting β-Catenin, and that WNK regulates the β-Catenin level. Furthermore, we show that WNK inhibitors induced β-Catenin degradation and that one of these inhibitors suppressed xenograft tumour development in mice. These results suggest that WNK is a previously unrecognized regulator of β-Catenin and a therapeutic target of cancer.

Sign in / Sign up

Export Citation Format

Share Document